1109 GMT - Fresenius Medical Care's update on its midterm targets looks positive, but broadly in line with elevated expectations, Barclays analysts say in a research note. Investors likely anticipated a 500 million-euro buyback, so news that the German dialysis company plans buybacks of 1 billion euros over two years is in line with expectations, the analysts say. The company is targeting an adjusted operating profit margin in the mid-teens by 2030. "Whilst we don't have reliable consensus out to 2030--consensus is at 12.0% for 2027--we believe this is likely in line with buyside expectations, which have been building into the [capital markets day]," Barclays says. Shares fall 4.1%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

June 17, 2025 07:09 ET (11:09 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.